The role of L1-CAM immunohistochemial staining in the diagnosis of abdominal-pelvic cancer of uncertain primary site in women

European Journal of Surgical Oncology

Volumn 34, Issue 7, 2008, Pages 795-799

  Ben Arie, A ^a   Huszar, M ^a   Ben Zvi, N ^a   Smirnov, A ^a   Altevogt, P ^b   Fogel, M ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CUP; Endometrial carcinoma; Immunohistochemistry; L1 CAM; Ovarian carcinoma

Indexed keywords

NERVE CELL ADHESION MOLECULE L1; TUMOR MARKER;

ABDOMINAL WALL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INGUINAL LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS; MUELLERIAN DUCT; OVARY CANCER; PELVIS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VAGINA CANCER;

ABDOMINAL NEOPLASMS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MULLERIAN DUCTS; NEOPLASMS, UNKNOWN PRIMARY; NEURAL CELL ADHESION MOLECULE L1; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 44949181026     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.07.010     Document Type: Article

References (14)

1. Varadhachary G.R., Abbruzzese J.L., and Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 100 (2004) 1776-1785
2. Dowell J.E. Cancer from an unknown primary site. Am J Med Sci 326 (2003) 35-46
3. Van de Wouw A.J., Janssen-Heijnen M.L., Coebergh J.W., and Hillen H.F. Epidemiology of unknown primary tumors; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 38 (2002) 409-413
4. Pavlidis N., Briasoulis E., Hainsworth J., and Greco F.A. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39 (2003) 1990-2005
5. Pavlidis N. Cancer of unknown primary: biological and clinical characteristics. Ann Oncol 14 (2003) 1-8
6. Fogel M., Gutwein P., Mechtersheimer S., et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 362 (2003) 869-875
7. Huszar M., Moldenhauer G., Gscwend V., Ben-Arie A., Altevogt P., and Fogel M. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 37 (2006) 1000-1008
8. Muir C. Cancer of unknown primary site. Cancer 75 (1995) 353-356
9. Jaback K.S., Ludeman L., Clayton N.L., and Hirschowitz L. Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. Int J Gynecol Cancer 16 (2006) 123-128
10. Milovic M., Popov I., and Jelic S. Tumor markers in metastatic disease from cancer of unknown primary origin. Med Sci Monit 8 (2002) 25-30
11. Greco F.A., and Hainsworth J.D. Cancer of unknown primary site. In: De Vita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 5th ed. (1997), Lippincott-Raven, Philadelphia 2423-2443
12. Van Der Gaast A., Verweij J., Henzen-Logmans S.C., Rodenburg C.J., and Stoter G. Carcinoma of unknown primary: identification of a treatable subset?. Ann Oncol 1 (1990) 119-122
13. Sumi H., Itoh K., Onozawa Y., et al. Treatable subsets in cancer of unknown primary origin. Jpn J Cancer Res 92 (2001 Jun) 704-709
14. Ayhan A., Guvenal T., Salman M.C., Ozyuncu O., Sakinci M., and Basaran M. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecol Oncol 98 (2005) 235-241